Latest Axel Ullrich Stories
TweetChat and Scientific Symposium to Highlight Groundbreaking Discovery and Future Applications NEW YORK, Sept.
SAN DIEGO, June 24, 2014 /PRNewswire/ -- Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr.
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
NEW BRUNSWICK, N.J., Dec. 14, 2010 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research today opens its 2011 call for nominations.
NEW BRUNSWICK, N.J., Jan. 11 /PRNewswire/ -- The Dr. Paul Janssen Award for Biomedical Research has opened the 2010 call for nominations. The $100,000 Award recognizes individuals whose efforts have made significant transformational contributions towards the improvement of human health.
BEERSE, Belgium, Sept. 8 /PRNewswire/ -- Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr.
LONDON, July 1 /PRNewswire/ -- Johnson & Johnson today announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin(R) (trastuzumab)*, is the winner of the 2009 Dr.